Pharma reinvented: localisation, regulation, and innovation in Africa’s new health economy

Africa’s pharmaceutical future will not be imported: it has to be more Made in Africa manufactured. As governments pursue universal health access and supply-chain resilience, the continent is accelerating local production of medicines, vaccines and diagnostics.

Morocco, host of GITEX FUTURE HEALTH AFRICA 2026, stands at the forefront of this shift with an ambitious 2030 Vision centred on localisation, regulatory modernisation, and innovation-driven growth. Its strategy is reshaping not only the national market but also setting a template for Africa’s broader pharmaceutical renaissance.

Why Africa is reinventing its pharmaceutical landscape

Africa currently imports over 70% of its pharmaceuticals, a dependency that the African Union has called “a structural vulnerability”.

The COVID-19 pandemic exposed this vulnerability, with global shortages, export bans and long procurement delays.

Three forces are now accelerating change:

1. Health sovereignty - ensuring medicines are available even during global shocks.
2. Universal health coverage - driving demand for generics, diagnostics and chronic-disease treatments.
3. Economic opportunity - according to some analysis, Africa’s pharmaceutical market can be projected to reach US$70–85 billion by 2030.

These are few of the reasons why Morocco’s national strategy positions the kingdom as a regional manufacturing and export hub.

Morocco’s 2030 Vision: building a regional pharmaceutical powerhouse

Morocco’s pharmaceutical sector is one of the most advanced in Africa, with more than 70% of medicines consumed locally produced, and exports reaching a large number of European countries, to North America, Africa, Asia and MENA region The country’s 2030 Vision for National Pharmaceutical Sovereignty is built on three pillars:

1. Local production scaling: from generics to biomanufacturing

Leading Moroccan manufacturers - including Sothema, Pharma 5, Cooper Pharma, and Laprophan - are expanding capacity for oncology drugs, insulin, vaccines and biosimilars.

• Cooper Pharma is investing in vaccine manufacturing partnerships, including projects aligned with Africa’s vaccine self-sufficiency goals.
• Sothema has regional operations in West Africa and is developing production lines for chronic-disease drugs.
• Pharma 5 is focusing on affordable generics and R&D for local health needs.

These investments align with the Africa CDC’s Partnership for African Vaccine Manufacturing (PAVM), which aims to manufacture 60% of Africa’s vaccines locally by 2040.

2. Regulatory modernisation: strengthening quality, safety and trust

Morocco is overhauling its regulatory architecture to support pharmaceutical innovation and export.

Key reforms include:

• Strengthening of ANAM (National Health Insurance Agency) and pharmaceutical pricing transparency.
• Alignment with WHO’s Global Benchmarking Tool for regulatory maturity.
• Digitalisation of market authorisations, inspections and pharmacovigilance.
• Integration of pharmaceutical traceability with the Dossier Médical Partagé (DMP).

These improvements position Morocco to reach WHO Maturity Level 3 regulator, enabling faster approvals and international regulatory recognition.

3. Logistics and supply-chain digitalisation

The Ministry of Health and local manufacturers are modernising the pharmaceutical supply chain through e-procurement for public hospitals, digital stock tracking to prevent shortages, cold-chain optimisation powered by IoT sensors, and partnerships with logistics firms for regional exports. This mirrors continental efforts under the Smart Africa Digital Health Blueprint, which calls for interoperable pharma supply chains across Africa.

Africa's regulatory and production momentum: reinforcing Morocco’s leadership

Morocco’s progress aligns with broader continental initiatives:

1. AfCFTA’s pharmaceutical strategy

The African Continental Free Trade Area (AfCFTA) is establishing common regulatory frameworks and pooled procurement mechanisms to lower costs and encourage intra-African trade.

2. Regional manufacturing clusters

Africa’s emerging hubs include:

• Rwanda - vaccine manufacturing partnerships under PAVM;
• Egypt - fast-growing generics and sterile injectables sector;
• South Africa - advanced biologics and active pharmaceutical ingredients (API) production;
• Ghana - FDA recognised as WHO Maturity Level 3 regulator

These reinforce the continental momentum that Morocco is strategically positioned to lead.

Innovation reshaping Africa’s pharma economy

1. Quality frameworks enabling competitive exports

Countries are aligning with:

• WHO GMP standards,
• ISO-certified quality laboratories, and
• harmonised pharmacovigilance frameworks under the African Medicines Agency (AMA).

The AMA, ratified in 2023, provides a regulatory umbrella that will reduce duplication, accelerate approvals, and improve safety monitoring.

2. Digital tools strengthening compliance and safety

Africa’s pharma industry is adopting technologies such as barcoding and RFID for anti-counterfeiting, blockchain-enabled tracking for high-value medicines, AI analytics for demand forecasting, cloud-based quality management systems. Counterfeit medicines account for up to 40% of the market in some African regions, making now digital traceability a public-health imperative.

3. Public-private partnerships accelerating growth

Morocco’s sovereign vehicles - including Ithmar Capital - are mobilising blended finance for pharma manufacturing. With health being one of the top 3 priority sectors, the African Development Bank (AfDB) is also financing regional pharmaceutical parks and quality-control laboratories.

These investment models are enabling scale that was previously unreachable for local producers.

Case studies across Africa reinforcing Morocco’s momentum

Rwanda – Africa’s next-generation vaccine hub

Rwanda is progressing with vaccine manufacturing partnerships under the PAVM strategy, backed by strong regulatory capacity.

South Africa – API and biologics leadership

South Africa continues to develop advanced biologics production capabilities, contributing to regional drug security.

Egypt – pharma industrial zone expansion

Egypt’s integrated pharma city model is strengthening regional supply for sterile injectables and generics.

Ghana – regulatory excellence

Ghana’s FDA achieving WHO Maturity Level 3 sets a new standard for African regulatory agencies. These examples highlight the continental movement Morocco is aligning itself with.

Toward GITEX FUTURE HEALTH AFRICA 2026: the new pharmaceutical conversation

At GITEX FUTURE HEALTH AFRICA 2026, the pharmaceutical agenda will spotlight:

• localisation strategies to reduce import dependency,
• cross-border regulatory harmonisation under AMA and AfCFTA,
• incentives for vaccine and biosimilar manufacturing,
• digital supply-chain and traceability solutions,
• PPP models for pharmaceutical innovation and export growth.

Conclusion

Africa’s pharmaceutical future will be built in Africa - and Morocco is already emerging as one of its strategic architects. With its 2030 Vision, strong regulatory reforms, and growing manufacturing base, Morocco is redefining what pharmaceutical sovereignty can look like on the continent. As African demand for quality, affordable medicines accelerates, and as global supply chains face new tensions, regionalised production is no longer aspirational - it is essential.

GITEX FUTURE HEALTH AFRICA 2026 will offer the stage where governments, industry leaders and innovators can shape the next decade of pharmaceutical independence and health security.